Comparison of backbone dynamics of the p50 dimerization domain of NFκB in the homodimeric transcription factor NFκB1 and in its heterodimeric complex with RelA (p65).
Nuclear factor of kappa light polypeptide gene enhancer in B-cells (NF) transcription factor plays an important role in the human immune response. family including homodimers and heterodimers five component proteins, which mediate transcription of different responses and binds preferentially to different DNA sequences.
DNA complex crystal structures showed that the dimers of Rel-homology region (RHR) is structurally very similar. DNA sequences of different preferences together with structural similarities indicate that the dimer may differ in their dynamics.
In this study, we present the first near-complete 15 N, 13 Cα / β, and HN backbone resonance assignment of domain dimerization of two dimer (DD) of NFκBp50) protein (residues 241-351): homodimers and heterodimers of two p50 domains of DD DD p50 to p65. As expected, the two dimers behave very similar, the chemical shift difference between them is mostly concentrated at the dimer interface and arising from certain differences in the amino acid sequence of p50 and p65.
Comparative dynamics of picosecond-nanosecond of homo and heterodimers also showed that the p50-like environment, with a slightly reduced the overall correlation to homodimer as compared to the heterodimer, consistent with a molecular weight slightly smaller. These results show that NMR spectroscopy can be used to explore the subtle changes in the structure and dynamics of which have the potential to provide insight into the differences in specificity that can be exploited in the design of new therapeutic agents. This article is protected by copyright. All rights reserved.
Comparison of backbone dynamics of the p50 dimerization domain of NFκB in the homodimeric transcription factor NFκB1 and in its heterodimeric complex with RelA (p65).
Diets high in n6 / n3 ratio decreased ratio of arachidonic acid and eicosapentaenoic regulate NF / p50 expression in short-term low-dose streptozotocin and high-fructose mouse model of diabetes.
We studied the effect of dietary n6 / n3 ratio and docosahexaenoic (DHA) and eicosapentaenoic (EPA) acid supplementation on fatty acid profile, lipid peroxidation and NFκ / p50 expression in type 2 diabetes treatment consisted of three dietary ratio of n6 / n3: 6 (Control ), 50 (high n6) and 1 (DHA and EPA plus).
Half of the rats in each treatment were made diabetic diet by using fructose / model low-streptozotocin. Control and high n6 loss diet EPA / ARA (arachidonic acid) ratio in the plasma and in the liver tissue showed pro-inflammatory fatty acid profile. High n6 diet also increases 4-HNE and NFκ / p50 expression in liver tissue. These changes are a consequence of a decrease in plasma levels of DHA and EPA and the increase in arachidonic acid content in the liver neutral lipids. Supplementation with DHA and EPA attenuated changes in the ratio of EPA / ARA, which implies the importance of n6 / n3 ratio in type 2 diabetes.
Immunoregulatory effects of polysaccharides new cornucopioides Craterellus (CCP) with a triple-helix structure in immunosuppressive BALB / c mouse model was investigated; moreover, the immune response of BALB / c mouse model in prevention and therapeutic treatment group were treated with PKC explored, and the molecular mechanisms that have been described. It was found that BALB / c mouse model in preventive group treated with CCP (120 and 240 mg kg-1 d-1) have a better immunoregulatory activity.
Description: A polyclonal antibody for NFkB p105 / p50 (pSer893) from Human. The antibody is produced in rabbit after immunization with human synthetic phospho-peptide from human NFkB p105 / p50 around the phosphorylation site of serine 893 (pSer893).. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:250-1:1000); IHC (1:25-1:100). This NFkB p105 / p50 (pSer893) antibody is conjugated to ATTO 565.
Description: A polyclonal antibody for NFkB p105 / p50 (pSer893) from Human. The antibody is produced in rabbit after immunization with human synthetic phospho-peptide from human NFkB p105 / p50 around the phosphorylation site of serine 893 (pSer893).. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:250-1:1000); IHC (1:25-1:100). This NFkB p105 / p50 (pSer893) antibody is conjugated to ATTO 633.
Description: A polyclonal antibody for NFkB p105 / p50 (pSer893) from Human. The antibody is produced in rabbit after immunization with human synthetic phospho-peptide from human NFkB p105 / p50 around the phosphorylation site of serine 893 (pSer893).. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:250-1:1000); IHC (1:25-1:100). This NFkB p105 / p50 (pSer893) antibody is conjugated to ATTO 655.
Description: A polyclonal antibody for NFkB p105 / p50 (pSer893) from Human. The antibody is produced in rabbit after immunization with human synthetic phospho-peptide from human NFkB p105 / p50 around the phosphorylation site of serine 893 (pSer893).. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:250-1:1000); IHC (1:25-1:100). This NFkB p105 / p50 (pSer893) antibody is conjugated to ATTO 680.
Description: A polyclonal antibody for NFkB p105 / p50 (pSer893) from Human. The antibody is produced in rabbit after immunization with human synthetic phospho-peptide from human NFkB p105 / p50 around the phosphorylation site of serine 893 (pSer893).. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:250-1:1000); IHC (1:25-1:100). This NFkB p105 / p50 (pSer893) antibody is conjugated to ATTO 700.
Description: A polyclonal antibody for NFkB p105 / p50 (pSer893) from Human. The antibody is produced in rabbit after immunization with human synthetic phospho-peptide from human NFkB p105 / p50 around the phosphorylation site of serine 893 (pSer893).. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:250-1:1000); IHC (1:25-1:100). This NFkB p105 / p50 (pSer893) antibody is conjugated to Alkaline Phosphatase.
Description: A polyclonal antibody for NFkB p105 / p50 (pSer893) from Human. The antibody is produced in rabbit after immunization with human synthetic phospho-peptide from human NFkB p105 / p50 around the phosphorylation site of serine 893 (pSer893).. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:250-1:1000); IHC (1:25-1:100). This NFkB p105 / p50 (pSer893) antibody is conjugated to APC .
Description: A polyclonal antibody for NFkB p105 / p50 (pSer893) from Human. The antibody is produced in rabbit after immunization with human synthetic phospho-peptide from human NFkB p105 / p50 around the phosphorylation site of serine 893 (pSer893).. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:250-1:1000); IHC (1:25-1:100). This NFkB p105 / p50 (pSer893) antibody is conjugated to APC/Cy7.
Description: A polyclonal antibody for NFkB p105 / p50 (pSer893) from Human. The antibody is produced in rabbit after immunization with human synthetic phospho-peptide from human NFkB p105 / p50 around the phosphorylation site of serine 893 (pSer893).. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:250-1:1000); IHC (1:25-1:100). This NFkB p105 / p50 (pSer893) antibody is conjugated to Dylight 350.
Description: A polyclonal antibody for NFkB p105 / p50 (pSer893) from Human. The antibody is produced in rabbit after immunization with human synthetic phospho-peptide from human NFkB p105 / p50 around the phosphorylation site of serine 893 (pSer893).. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:250-1:1000); IHC (1:25-1:100). This NFkB p105 / p50 (pSer893) antibody is conjugated to Dylight 405.
Description: A polyclonal antibody for NFkB p105 / p50 (pSer893) from Human. The antibody is produced in rabbit after immunization with human synthetic phospho-peptide from human NFkB p105 / p50 around the phosphorylation site of serine 893 (pSer893).. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:250-1:1000); IHC (1:25-1:100). This NFkB p105 / p50 (pSer893) antibody is conjugated to Dylight 488.
Description: A polyclonal antibody for NFkB p105 / p50 (pSer893) from Human. The antibody is produced in rabbit after immunization with human synthetic phospho-peptide from human NFkB p105 / p50 around the phosphorylation site of serine 893 (pSer893).. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:250-1:1000); IHC (1:25-1:100). This NFkB p105 / p50 (pSer893) antibody is conjugated to Dylight 594.
Description: A polyclonal antibody for NFkB p105 / p50 (pSer893) from Human. The antibody is produced in rabbit after immunization with human synthetic phospho-peptide from human NFkB p105 / p50 around the phosphorylation site of serine 893 (pSer893).. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:250-1:1000); IHC (1:25-1:100). This NFkB p105 / p50 (pSer893) antibody is conjugated to Dylight 633.
Description: A polyclonal antibody for NFkB p105 / p50 (pSer893) from Human. The antibody is produced in rabbit after immunization with human synthetic phospho-peptide from human NFkB p105 / p50 around the phosphorylation site of serine 893 (pSer893).. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:250-1:1000); IHC (1:25-1:100). This NFkB p105 / p50 (pSer893) antibody is conjugated to HRP.
Description: A polyclonal antibody for NFkB p105 / p50 (pSer893) from Human. The antibody is produced in rabbit after immunization with human synthetic phospho-peptide from human NFkB p105 / p50 around the phosphorylation site of serine 893 (pSer893).. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:250-1:1000); IHC (1:25-1:100). This NFkB p105 / p50 (pSer893) antibody is conjugated to PE/ATTO 594.
Description: A polyclonal antibody for NFkB p105 / p50 (pSer893) from Human. The antibody is produced in rabbit after immunization with human synthetic phospho-peptide from human NFkB p105 / p50 around the phosphorylation site of serine 893 (pSer893).. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:250-1:1000); IHC (1:25-1:100). This NFkB p105 / p50 (pSer893) antibody is conjugated to PerCP.
Description: A polyclonal antibody for NFkB p105 / p50 (pSer893) from Human. The antibody is produced in rabbit after immunization with human synthetic phospho-peptide from human NFkB p105 / p50 around the phosphorylation site of serine 893 (pSer893).. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:250-1:1000); IHC (1:25-1:100). This NFkB p105 / p50 (pSer893) antibody is conjugated to RPE .
Description: A polyclonal antibody for NFkB p105 / p50 (pSer893) from Human. The antibody is produced in rabbit after immunization with human synthetic phospho-peptide from human NFkB p105 / p50 around the phosphorylation site of serine 893 (pSer893).. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:250-1:1000); IHC (1:25-1:100). This NFkB p105 / p50 (pSer893) antibody is conjugated to Streptavidin.
Description: A polyclonal antibody for NFkB p105 / p50 (pSer907) from Human. The antibody is produced in rabbit after immunization with human synthetic phospho-peptide from human NFkB p105 / p50 around the phosphorylation site of serine 907 (pSer907).. The Antibody is tested and validated for WB, IHC, IP assays with the following recommended dilutions: WB (1:250-1:1000); IHC (1:25-1:100); IP (Various dilutions). This NFkB p105 / p50 (pSer907) antibody is conjugated to ATTO 565.
Description: A polyclonal antibody for NFkB p105 / p50 (pSer907) from Human. The antibody is produced in rabbit after immunization with human synthetic phospho-peptide from human NFkB p105 / p50 around the phosphorylation site of serine 907 (pSer907).. The Antibody is tested and validated for WB, IHC, IP assays with the following recommended dilutions: WB (1:250-1:1000); IHC (1:25-1:100); IP (Various dilutions). This NFkB p105 / p50 (pSer907) antibody is conjugated to ATTO 633.
Description: A polyclonal antibody for NFkB p105 / p50 (pSer907) from Human. The antibody is produced in rabbit after immunization with human synthetic phospho-peptide from human NFkB p105 / p50 around the phosphorylation site of serine 907 (pSer907).. The Antibody is tested and validated for WB, IHC, IP assays with the following recommended dilutions: WB (1:250-1:1000); IHC (1:25-1:100); IP (Various dilutions). This NFkB p105 / p50 (pSer907) antibody is conjugated to ATTO 655.
Description: A polyclonal antibody for NFkB p105 / p50 (pSer907) from Human. The antibody is produced in rabbit after immunization with human synthetic phospho-peptide from human NFkB p105 / p50 around the phosphorylation site of serine 907 (pSer907).. The Antibody is tested and validated for WB, IHC, IP assays with the following recommended dilutions: WB (1:250-1:1000); IHC (1:25-1:100); IP (Various dilutions). This NFkB p105 / p50 (pSer907) antibody is conjugated to ATTO 680.
Description: A polyclonal antibody for NFkB p105 / p50 (pSer907) from Human. The antibody is produced in rabbit after immunization with human synthetic phospho-peptide from human NFkB p105 / p50 around the phosphorylation site of serine 907 (pSer907).. The Antibody is tested and validated for WB, IHC, IP assays with the following recommended dilutions: WB (1:250-1:1000); IHC (1:25-1:100); IP (Various dilutions). This NFkB p105 / p50 (pSer907) antibody is conjugated to ATTO 700.
Description: A polyclonal antibody for NFkB p105 / p50 (pSer907) from Human. The antibody is produced in rabbit after immunization with human synthetic phospho-peptide from human NFkB p105 / p50 around the phosphorylation site of serine 907 (pSer907).. The Antibody is tested and validated for WB, IHC, IP assays with the following recommended dilutions: WB (1:250-1:1000); IHC (1:25-1:100); IP (Various dilutions). This NFkB p105 / p50 (pSer907) antibody is conjugated to Alkaline Phosphatase.
Description: A polyclonal antibody for NFkB p105 / p50 (pSer907) from Human. The antibody is produced in rabbit after immunization with human synthetic phospho-peptide from human NFkB p105 / p50 around the phosphorylation site of serine 907 (pSer907).. The Antibody is tested and validated for WB, IHC, IP assays with the following recommended dilutions: WB (1:250-1:1000); IHC (1:25-1:100); IP (Various dilutions). This NFkB p105 / p50 (pSer907) antibody is conjugated to APC .
Description: A polyclonal antibody for NFkB p105 / p50 (pSer907) from Human. The antibody is produced in rabbit after immunization with human synthetic phospho-peptide from human NFkB p105 / p50 around the phosphorylation site of serine 907 (pSer907).. The Antibody is tested and validated for WB, IHC, IP assays with the following recommended dilutions: WB (1:250-1:1000); IHC (1:25-1:100); IP (Various dilutions). This NFkB p105 / p50 (pSer907) antibody is conjugated to APC/Cy7.
Description: A polyclonal antibody for NFkB p105 / p50 (pSer907) from Human. The antibody is produced in rabbit after immunization with human synthetic phospho-peptide from human NFkB p105 / p50 around the phosphorylation site of serine 907 (pSer907).. The Antibody is tested and validated for WB, IHC, IP assays with the following recommended dilutions: WB (1:250-1:1000); IHC (1:25-1:100); IP (Various dilutions). This NFkB p105 / p50 (pSer907) antibody is conjugated to Dylight 350.
Description: A polyclonal antibody for NFkB p105 / p50 (pSer907) from Human. The antibody is produced in rabbit after immunization with human synthetic phospho-peptide from human NFkB p105 / p50 around the phosphorylation site of serine 907 (pSer907).. The Antibody is tested and validated for WB, IHC, IP assays with the following recommended dilutions: WB (1:250-1:1000); IHC (1:25-1:100); IP (Various dilutions). This NFkB p105 / p50 (pSer907) antibody is conjugated to Dylight 405.
Description: A polyclonal antibody for NFkB p105 / p50 (pSer907) from Human. The antibody is produced in rabbit after immunization with human synthetic phospho-peptide from human NFkB p105 / p50 around the phosphorylation site of serine 907 (pSer907).. The Antibody is tested and validated for WB, IHC, IP assays with the following recommended dilutions: WB (1:250-1:1000); IHC (1:25-1:100); IP (Various dilutions). This NFkB p105 / p50 (pSer907) antibody is conjugated to Dylight 488.
Description: A polyclonal antibody for NFkB p105 / p50 (pSer907) from Human. The antibody is produced in rabbit after immunization with human synthetic phospho-peptide from human NFkB p105 / p50 around the phosphorylation site of serine 907 (pSer907).. The Antibody is tested and validated for WB, IHC, IP assays with the following recommended dilutions: WB (1:250-1:1000); IHC (1:25-1:100); IP (Various dilutions). This NFkB p105 / p50 (pSer907) antibody is conjugated to Dylight 594.
Description: A polyclonal antibody for NFkB p105 / p50 (pSer907) from Human. The antibody is produced in rabbit after immunization with human synthetic phospho-peptide from human NFkB p105 / p50 around the phosphorylation site of serine 907 (pSer907).. The Antibody is tested and validated for WB, IHC, IP assays with the following recommended dilutions: WB (1:250-1:1000); IHC (1:25-1:100); IP (Various dilutions). This NFkB p105 / p50 (pSer907) antibody is conjugated to Dylight 633.
Description: A polyclonal antibody for NFkB p105 / p50 (pSer907) from Human. The antibody is produced in rabbit after immunization with human synthetic phospho-peptide from human NFkB p105 / p50 around the phosphorylation site of serine 907 (pSer907).. The Antibody is tested and validated for WB, IHC, IP assays with the following recommended dilutions: WB (1:250-1:1000); IHC (1:25-1:100); IP (Various dilutions). This NFkB p105 / p50 (pSer907) antibody is conjugated to HRP.
Description: A polyclonal antibody for NFkB p105 / p50 (pSer907) from Human. The antibody is produced in rabbit after immunization with human synthetic phospho-peptide from human NFkB p105 / p50 around the phosphorylation site of serine 907 (pSer907).. The Antibody is tested and validated for WB, IHC, IP assays with the following recommended dilutions: WB (1:250-1:1000); IHC (1:25-1:100); IP (Various dilutions). This NFkB p105 / p50 (pSer907) antibody is conjugated to PE/ATTO 594.
Description: A polyclonal antibody for NFkB p105 / p50 (pSer907) from Human. The antibody is produced in rabbit after immunization with human synthetic phospho-peptide from human NFkB p105 / p50 around the phosphorylation site of serine 907 (pSer907).. The Antibody is tested and validated for WB, IHC, IP assays with the following recommended dilutions: WB (1:250-1:1000); IHC (1:25-1:100); IP (Various dilutions). This NFkB p105 / p50 (pSer907) antibody is conjugated to PerCP.
Description: A polyclonal antibody for NFkB p105 / p50 (pSer907) from Human. The antibody is produced in rabbit after immunization with human synthetic phospho-peptide from human NFkB p105 / p50 around the phosphorylation site of serine 907 (pSer907).. The Antibody is tested and validated for WB, IHC, IP assays with the following recommended dilutions: WB (1:250-1:1000); IHC (1:25-1:100); IP (Various dilutions). This NFkB p105 / p50 (pSer907) antibody is conjugated to RPE .
Description: A polyclonal antibody for NFkB p105 / p50 (pSer907) from Human. The antibody is produced in rabbit after immunization with human synthetic phospho-peptide from human NFkB p105 / p50 around the phosphorylation site of serine 907 (pSer907).. The Antibody is tested and validated for WB, IHC, IP assays with the following recommended dilutions: WB (1:250-1:1000); IHC (1:25-1:100); IP (Various dilutions). This NFkB p105 / p50 (pSer907) antibody is conjugated to Streptavidin.
Spleen and thymus weight index of the model BALB / c mice increased significantly, and histopathological analysis showed a protective function of the CCP against immunosuppression caused by cyclophosphamide (CTX). In addition, the CCP has shown synergistic effects were definitely and clearly on T or B-lymphocyte proliferation induced by Cona or LPS, respectively, to promote natural killer (NK) cell activity and significantly increase the activity of phagocytes to activate peritoneal macrophages in mice immunosuppressive.
Antibodies | Assay Kits | Biology Cells | cDNA | Clia Kits | Culture Cells | Devices | DNA | DNA Templates | DNA Testing | Elisa Kits | Enzymes | Equipments | Exosomes | Gels | Isotypes | Medium & Serums | NATtrol | Panel | Particles | PCR | Pcr Kits | Peptides | Reagents | Recombinant Proteins | Ria Kits | RNA | Test Kits | Uncategorized | Vector & Virus | Western Blot 
Antibodies | Assay Kits | Biology Cells | cDNA | Clia Kits | Culture Cells | Devices | DNA | DNA Templates | DNA Testing | Elisa Kits | Enzymes | Equipments | Exosomes | Gels | Isotypes | Medium & Serums | NATtrol | Panel | Particles | PCR | Pcr Kits | Peptides | Reagents | Recombinant Proteins | Ria Kits | RNA | Test Kits | Uncategorized | Vector & Virus | Western Blot 
Antibodies | Assay Kits | Biology Cells | cDNA | Clia Kits | Culture Cells | Devices | DNA | DNA Templates | DNA Testing | Elisa Kits | Enzymes | Equipments | Exosomes | Gels | Isotypes | Medium & Serums | NATtrol | Panel | Particles | PCR | Pcr Kits | Peptides | Reagents | Recombinant Proteins | Ria Kits | RNA | Test Kits | Uncategorized | Vector & Virus | Western Blot 
Antibodies | Assay Kits | Biology Cells | cDNA | Clia Kits | Culture Cells | Devices | DNA | DNA Templates | DNA Testing | Elisa Kits | Enzymes | Equipments | Exosomes | Gels | Isotypes | Medium & Serums | NATtrol | Panel | Particles | PCR | Pcr Kits | Peptides | Reagents | Recombinant Proteins | Ria Kits | RNA | Test Kits | Uncategorized | Vector & Virus | Western Blot
No Comment